MT2022-01: MSCs for ALD

Masonic Cancer Center, University of Minnesota10 enrolled

Overview

This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT. The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cerebral Adrenoleukodystrophy

Interventions

Mesenchymal stem cells (IV-MSC)BIOLOGICAL

Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.

Eligibility

Sex: ALLMin age: 3 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age ≥ 3 years * diagnosis of ALD, as established by elevation of very long chain fatty acid levels or gene mutation * evidence of active cerebral disease as determined by the presence of gadolinium enhancement * ALD MRI (Loes) score ≥ 1 * Patients who have not received prior gene therapy or transplant * Life expectancy of \> 6 months as determined by the enrolling researcher * Have adequate organ function confirmed by laboratory values obtained within 28 days prior to enrollment Exclusion Criteria: * Inability to undergo sedation or MRI studies for any reason * Other concurrent life-threatening disease (life expectancy \<6 months) or eligible for hospice care * Known or suspected hypersensitivity to human serum albumin, diphenhydramine, acetaminophen, methylprednisolone, or any of the components of IMS001.

Locations (1)

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Safety and tolerability of intravenously-administered allogeneic, third-party mesenchymal stem cells (IV-MSC).

Safety and tolerability of cerebral adrenoleukodystrophy (cALD) patients receiving intravenously-administered allogeneic, third-party mesenchymal stem cells (IV-MSC) assessed by incidence of adverse events.

Time frame: 6 months

Secondary Outcomes

Incidence of radiographic response in patients receiving intravenously-administered allogeneic, third-party mesenchymal stem cells (IV-MSC).

Radiographic response is defined as the resolution of intravenous gadolinium contrast enhancement on brain MRI.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.